Tata Laksana Oklusi Vena Retina Sentral
DOI:
https://doi.org/10.55175/cdk.v51i1.669Keywords:
Central retinal vein occlusion, visual acuity, management of CRVOAbstract
Central retinal vein occlusion (CRVO) is a condition caused by retinal vein occlusion at the central or posterior of the optic nerve due to a thrombus. Risk factors are age, cardiovascular disease, and systemic disease. The incidence of CRVO in men and women is the same and most commonly occurs at the age of more than 50 years. The manifestation of decreased visual acuity in CRVO is associated with macula edema. Management of CRVO can be in the form of medication and arrest and modification of risk factors. Early detection and prompt treatment are important to preserve visual acuity.
Downloads
References
American Academy of Ophthalmology. Retinal vein occlusion. Retina and vitreous. Section 12. San Francisco; p. 2021-2.
Ichsan AM, Andayani A, Kartasasmita AS, et al. Pedoman penanganan oklusi vena retina di Indonesia. Perdami Seminat Vitreoretina; 2019.
The Royal College of Opthalmologists. Clinical guidelines: Retinal vein occlusion (RVO) [Internet]. 2022. Available from: https://www.rcophth. ac.uk/wp-content/uploads/2015/07/Retinal-Vein-Occlusion-Guidelines-2022.pdf.
Sinawat S, Bunyavee C, Ratanapokorn T, Sinawat S, Laovirojjanakul W, Yospaiboon Y. Systemic abnormalities associated with retinal vein occlusion in young patients. Clin Ophthalmol. 2017;11:441-7.
Hayreh SS. Retinal vein occlusion. Indian J Ophthalmol. 1994;42:109-32.
Thomas AS, Thomas MK, Finn AP, Fekrat S. Use of the ischemic index on widefield fluorescein angiography to characterize a central retinal vein occlusion as ischemic or nonischemic. Retina 2019;39(6):1033-8.
Compendium EM. OZURDEX summary of product characteristics [Internet]. 2010. Available from: http://www.medicines.org.uk/EMC/medicine/23422/SPC/Ozurdex/.
Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127(9):1101-14.
National Institute for Health and Care Excellence. Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion: Technology appraisal guidance (TA 283) [Internet]. 2013. Available from: https://www.nice.org.uk/guidance/ta283
Group CRVOS. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997;115:486-91.
Larsen M, Waldstein SM, Priglinger S, Hykin P, Barnes E, Gekkieva M, et al. Sustained benefits from ranibizumab for central retinal vein occlusion with macular edema: 24-month results of the CRYSTAL study. Ophthalmol Retina 2018;2(2):134-42.
Campochiaro PA, Wykoff CC, Singer M, Johnson R, Marcus D, Yau L, et al. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: The SHORE study. Ophthalmology 2014;121(12):2432-42.
Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Altaweel M, et al. Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications: Secondary outcomes from the SCORE2 randomized clinical trial. JAMA Ophthalmol. 2018;136(4):337-45.
Kaya F, Kocak I, Aydin A, Baybora H, Koc H, Karabela Y. Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion. J Francais d’Ophthalmologie 2018;2062:1-5.
Simsek M, Citirik M, Ozates S, Ozkoyuncu D. The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusionrelated macular edema in a real-life Scenario. Indian J Ophthalmol. 2019;66(6):831-6.
Central Retinal Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997;115:486 – 91.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Elvira
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
